docetaxel + cyclophosphamide + trastuzumab

This is a combination regimen consisting of three drugs—docetaxel, cyclophosphamide, and trastuzumab—used primarily in the treatment of HER2-positive breast cancer. - **Docetaxel** is a taxane-class small molecule chemotherapeutic that inhibits microtubule depolymerization, disrupting mitosis and leading to cell death. - **Cyclophosphamide** is an alkylating agent (small molecule) that crosslinks DNA strands, preventing cell division and causing apoptosis in rapidly dividing cells. - **Trastuzumab** is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2), inhibiting downstream signaling pathways involved in tumor growth and survival. The combination has been studied as both neoadjuvant (pre-surgical) and adjuvant (post-surgical) therapy for early-stage or operable HER2-positive breast cancer. It offers an anthracycline-free option with demonstrated efficacy in achieving pathological complete response rates around 44–46%[1][3][4]. The regimen may be preferred for patients at risk of cardiac toxicity from anthracyclines[3][4].

Brand names

TaxotereHerceptinPerjeta

Other names

HER-TCTCH